APOA1 and Hypertension: Although several nutraceuticals have been reported to induce lipid-lowering [53] and arterial hypertension [54], the beneficial functions of lipid-free apoA-I and HDL can be impaired by oxidation and glycation, resulting in amyloid formation and aggregation [55, 56].